Olema Pharmaceuticals Net Worth

Olema Pharmaceuticals Net Worth Breakdown

  OLMA
The net worth of Olema Pharmaceuticals is the difference between its total assets and liabilities. Olema Pharmaceuticals' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Olema Pharmaceuticals' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Olema Pharmaceuticals' net worth can be used as a measure of its financial health and stability which can help investors to decide if Olema Pharmaceuticals is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Olema Pharmaceuticals stock.

Olema Pharmaceuticals Net Worth Analysis

Olema Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Olema Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Olema Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Olema Pharmaceuticals' net worth analysis. One common approach is to calculate Olema Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Olema Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Olema Pharmaceuticals' net worth. This approach calculates the present value of Olema Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Olema Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Olema Pharmaceuticals' net worth. This involves comparing Olema Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Olema Pharmaceuticals' net worth relative to its peers.
To determine if Olema Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Olema Pharmaceuticals' net worth research are outlined below:
Olema Pharmaceuticals generated a negative expected return over the last 90 days
Olema Pharmaceuticals has high historical volatility and very poor performance
Olema Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (129.47 M) with profit before overhead, payroll, taxes, and interest of 0.
Olema Pharmaceuticals currently holds about 240.71 M in cash with (104.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Olema Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 97.0% of the company shares are owned by institutional investors
Olema Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Olema Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Olema Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
14th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Follow Olema Pharmaceuticals' market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 281.53 M.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Olema Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Olema Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Olema Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Bohen Sean over two weeks ago
Acquisition by Bohen Sean of 650000 shares of Olema Pharmaceuticals at 4.37 subject to Rule 16b-3
 
Mitchell Shawnte over a month ago
Insider Trading
 
Bain Capital Life Sciences Investors, Llc over two months ago
Insider Trading
 
Graham G. Walmsley over three months ago
Disposition of 700761 shares by Graham G. Walmsley of Olema Pharmaceuticals at 6.75 subject to Rule 16b-3
 
Zojwalla Naseem over three months ago
Disposition of 14000 shares by Zojwalla Naseem of Olema Pharmaceuticals at 4.87 subject to Rule 16b-3
 
Graham G. Walmsley over three months ago
Disposition of 700761 shares by Graham G. Walmsley of Olema Pharmaceuticals at 6.75 subject to Rule 16b-3
 
Bohen Sean over three months ago
Disposition of 1267 shares by Bohen Sean of Olema Pharmaceuticals at 9. subject to Rule 16b-3
 
Bvf Partners L P/il over three months ago
Acquisition by Bvf Partners L Pil of 153441 shares of Olema Pharmaceuticals at 1.0E-4 subject to Rule 16b-3
 
Kovacs Shane William Charles over three months ago
Acquisition by Kovacs Shane William Charles of 25000 shares of Olema Pharmaceuticals at 7.02 subject to Rule 16b-3
 
Larson Yi over three months ago
Acquisition by Larson Yi of 23000 shares of Olema Pharmaceuticals at 12.36 subject to Rule 16b-3
 
Cyrus Harmon over six months ago
Disposition of 934 shares by Cyrus Harmon of Olema Pharmaceuticals at 15.55 subject to Rule 16b-3
 
Cyrus Harmon over six months ago
Disposition of 4066 shares by Cyrus Harmon of Olema Pharmaceuticals at 15.58 subject to Rule 16b-3
Olema Pharmaceuticals time-series forecasting models is one of many Olema Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Olema Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Olema Pharmaceuticals Earnings per Share Projection vs Actual

Olema Pharmaceuticals Corporate Management

JD MoriartyCorporate SecretaryProfile
Peter KushnerCoFounder FellowProfile
PharmD FaltaosVP PharmacologyProfile
Kinney HornChief OfficerProfile
Cyrus HarmonChief DirectorProfile
Courtney DuganVP CommunicationsProfile
John MoriartyChief VPProfile
When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.